Results 61 to 70 of about 1,395,322 (291)

Employment in New York City Publishing: Industry Group Profile [PDF]

open access: yes, 2009
One of nine industry group profiles designed to help workforce development professionals in New York City better understand employment prospects. Included in this report are job and wage trends, occupational opportunities for individuals without a ...
L. Hachadoorian, L. Hirsch
core  

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

open access: yesMolecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser   +14 more
wiley   +1 more source

Academic publishing in Nepal

open access: yesJournal of Karnali Academy of Health Sciences, 2022
Globally academic publishing is a high profit industry. Most of the work associated with manuscripts is carried out by academics for free. The article examines the academic publishing industry in Nepal.
Pathiyil Ravi Shankar   +2 more
doaj  

Academic Publishing, Internet Technology, and Disruptive Innovation

open access: yesTechnology Innovation Management Review, 2017
After 350 years of operation, the academic journal publishing industry is imbalanced and in flux as a result of the impacts of Internet technology, which has led, over the past 20 years, to the rise of open access publishing.
Haven Allahar
doaj   +1 more source

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

open access: yesMolecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu   +18 more
wiley   +1 more source

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

open access: yesMolecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker   +16 more
wiley   +1 more source

Navigating the Copyright Landscape: Iran's Journey towards Global Integration [PDF]

open access: yesInternational Journal of Information Science and Management
This study aims to explore the issues, factors, and outcomes of Iran's accession to international copyright treaties, offering practical recommendations. The research uses a qualitative approach with grounded theory methodology.
Dariush Matlabi
doaj   +1 more source

Innovation and Organisation in the UK magazine print publishing industry: a survey [PDF]

open access: yes, 2005
This paper examines innovation within the UK magazine publishing industry. We find that publishers are able to engage with niche interest groups in order to supply a high value-added product.
Cox, Howard, Mowatt, S., Young, S.
core   +2 more sources

Feasibility of a ctDNA multigenic panel for non‐small‐cell lung cancer early detection and disease surveillance

open access: yesMolecular Oncology, EarlyView.
Plasma‐based detection of actionable mutations is a promising approach in lung cancer management. Analysis of ctDNA with a multigene NGS panel identified TP53, KRAS, and EGFR as the most frequently altered, with TP53 and KRAS in treatment‐naïve patients and TP53 and EGFR in previously treated patients.
Giovanna Maria Stanfoca Casagrande   +11 more
wiley   +1 more source

Aggressive prostate cancer is associated with pericyte dysfunction

open access: yesMolecular Oncology, EarlyView.
Tumor‐produced TGF‐β drives pericyte dysfunction in prostate cancer. This dysfunction is characterized by downregulation of some canonical pericyte markers (i.e., DES, CSPG4, and ACTA2) while maintaining the expression of others (i.e., PDGFRB, NOTCH3, and RGS5).
Anabel Martinez‐Romero   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy